Compare · CNC vs NVTA
CNC vs NVTA
Side-by-side comparison of Centene Corporation (CNC) and Invitae Corporation (NVTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNC and NVTA operate in Medical Specialities (Health Care), so they compete in similar markets.
- CNC is the larger of the two at $34.83B, about 15.1x NVTA ($2.31B).
- CNC has hit the wire 12 times in the past 4 weeks while NVTA has been quiet.
- CNC has more recent analyst coverage (25 ratings vs 18 for NVTA).
- Company
- Centene Corporation
- Invitae Corporation
- Price
- -
- -
- Market cap
- $34.83B
- $2.31B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- 2015
- News (4w)
- 12
- 0
- Recent ratings
- 25
- 18
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Invitae Corporation
Invitae Corporation, a medical genetics company, integrates genetic information into healthcare decision-making by clinicians and patients in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Latest CNC
- Centene Corporation Demonstrates Commitment to CHOICE Arrangements through Benefit Programs in Indiana, Ohio and Oklahoma
- SEC Form 4 filed by Centene Corporation
- PA Health & Wellness Earns National Recognition Among Top Medicaid Health Plans for Second Consecutive Year
- Centene to Launch Nationwide Gold Card Program for Qualifying Providers
- SEC Form 8-K filed by Centene Corporation
- Ambetter Health Solutions and Marathon Health Expand Access to Primary Care for Members in Indiana and Missouri
- Wellcare Unveils 2027 Medicare Offerings Focused on Affordability and Integrated Care
- Director Tyler Lauren M was granted 482 shares, increasing direct ownership by 15% to 3,698 units (SEC Form 4)
- Director Tanji Kenneth was granted 603 shares, increasing direct ownership by 5% to 13,093 units (SEC Form 4)
- Director Samuels Theodore R. Ii was granted 583 shares, increasing direct ownership by 2% to 25,796 units (SEC Form 4)
Latest NVTA
- Citizen Health Raises $30 Million to Build AI Advocate for Every Patient, Ushering in a New Era of Patient-Centered Healthcare
- Labcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae Deal
- Reported Earlier, Labcorp Wins Bid For Invitae Assets To Boost Specialty Testing In Oncology And Rare Diseases
- Labcorp Announces Winning Bid for Select Assets of Invitae
- Invitae Enters into Agreement with Labcorp for Sale of Business
- Invitae Publishes its Environmental, Social and Governance (ESG) Report
- Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance
- Invitae Launches Update to Invitae Generation™: Clinical Variant Modeling Improves Variant Classification
- Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results
- Invitae to Present Data at the 2024 ACMG Annual Clinical Genetics Meeting